← Back to Search

Phosphodiesterase Inhibitor

Cilostazol for Heart Failure

Phase 2
Waitlist Available
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
>18 yrs
LVEF ≥ 50% (on last assessment, <2 years)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1st and 3rd week
Awards & highlights

Study Summary

This study is evaluating whether a drug called cilostazol might improve symptoms and blood markers in people with heart failure with preserved ejection fraction.

Eligible Conditions
  • Heart Failure

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1st and 3rd week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1st and 3rd week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
KCCQ-12
Secondary outcome measures
NTproBNP

Trial Design

2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment2 Interventions
First week, Placebo twice a day Second week, Cilostazol 100mg twice a day Third week, Placebo twice a day Forth week, Cilostazol 100mg twice a day
Group II: CilostazolExperimental Treatment2 Interventions
First week, Cilostazol 100mg twice a day Second week, Placebo twice a day Third week, Cilostazol 100mg twice a day Forth week, Placebo twice a day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cilostazol 100Mg Tab
2021
Completed Phase 2
~30
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,367 Previous Clinical Trials
1,587,484 Total Patients Enrolled
10 Trials studying Heart Failure
5,736 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Mar 2025